Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Exenatide. Amylin/Eli Lilly.

Nick Giannoukakis1

  • 1University of Pittsburgh School of Medicine, Diabetes Institute, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA. ngiann1@pitt.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|June 18, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal proteomics of leptin treatment in humans with acute and chronic energy deficiency-induced hypoleptinemia reveal novel, mainly immune-related, pleiotropic effects.

Metabolism: clinical and experimental·2024
Same author

Editorial: Diabetes and non-alcoholic fatty liver disease: points of physiological and mechanistic intersection and current co-therapeutic approaches.

Frontiers in endocrinology·2023
Same author

Uncoupling hepatic insulin resistance - hepatic inflammation to improve insulin sensitivity and to prevent impaired metabolism-associated fatty liver disease in type 2 diabetes.

Frontiers in endocrinology·2023
Same author

Tolerogenic dendritic cells in type 1 diabetes: no longer a concept.

Frontiers in immunology·2023
Same author

Response to Comment on Pietropaolo et al. Incidence of an Insulin-Requiring Hyperglycemic Syndrome in SARS-CoV-2- Infected Young Individuals: Is It Type 1 Diabetes? Diabetes 2022;71:2656-2663.

Diabetes·2022
Same author

Hydrogel Dressings for Chronic Wound Healing in Diabetes: Beyond Hydration.

Journal of pharmaceutics & drug delivery research·2022
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Exenatide, a synthetic GLP-1 agonist from Gila monster venom, is being developed as an injectable type 2 diabetes treatment. Multiple Phase III trials are evaluating exenatide as monotherapy and in combination with other diabetes medications.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Drug Development

Background:

  • Type 2 diabetes is a chronic metabolic disorder characterized by hyperglycemia.
  • Current treatments aim to improve insulin sensitivity and secretion.
  • Novel therapeutic agents are needed to manage type 2 diabetes effectively.

Purpose of the Study:

  • To evaluate exenatide, a synthetic glucagon-like peptide-1 (GLP-1) agonist, as a potential injectable treatment for type 2 diabetes.
  • To assess the efficacy and safety of exenatide in various treatment regimens.

Main Methods:

  • Initiation of three Phase III clinical trials for exenatide (AC-2993; synthetic exendin-4).
  • Trial 1: Exenatide as monotherapy.
  • Trial 2: Exenatide in conjunction with sulfonylureas.

Related Experiment Videos

  • Trial 3: Exenatide in combination with metformin and sulfonylureas.

    • Main Results:

    • Phase III trials were initiated to investigate exenatide's therapeutic potential.
    • The trials are designed to assess exenatide's efficacy in different patient populations and treatment combinations.

    Conclusions:

    • Exenatide shows promise as a novel injectable treatment for type 2 diabetes.
    • Ongoing Phase III trials will provide critical data on its clinical utility.